5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Acute O
Critical O
Illness O
: O
Potential O
benefit O
of O
treatment O
continuation O
should O
be O
weighed O
against O
the O
potential O
risk O
( O
5.1 O
) O
* O
Prader-Willi O
syndrome O
in O
Children O
: O
Evaluate O
for O
signs O
of O
upper O
airway O
obstruction O
and O
sleep O
apnea O
before O
initiation O
of O
treatmentDiscontinue O
treatment O
if O
these O
signs O
occur O
( O
5.2 O
) O
* O
Neoplasm O
: O
Monitor O
patients O
with O
preexisting O
tumors O
for O
progression O
or O
recurrence O
. O

Increased O
risk O
of O
a O
second O
neoplasm O
in O
childhood O
cancer O
survivors O
treated O
with O
somatropin O
in O
particular O
meningiomas O
in O
patients O
treated O
with O
radiation O
to O
the O
head O
for O
their O
first O
neoplasm O
( O
5.3 O
) O
* O
Impaired O
Glucose O
Tolerance O
and O
Diabetes O
Mellitus O
: O
May O
be O
unmaskedPeriodically O
monitor O
glucose O
levels O
in O
all O
patients O
. O

Doses O
of O
concurrent O
antihyperglycemic O
drugs O
in O
diabetics O
may O
require O
adjustment O
( O
5.4 O
) O
* O
Intracranial O
Hypertension O
: O
Exclude O
preexisting O
papilledema O
. O

May O
develop O
and O
is O
usually O
reversible O
after O
discontinuation O
or O
dose O
reduction O
( O
5.5 O
) O
* O
Hypersensitivity O
: O
Serious O
hypersensitivity O
reactions O
may O
occur O
. O

In O
the O
event O
of O
an O
allergic O
reaction O
, O
seek O
prompt O
medical O
attention O
( O
5.6 O
) O
* O
Fluid O
Retention O
( O
i.e. O
, O
edema O
, O
arthralgia O
, O
carpal O
tunnel O
syndrome O
- O
especially O
in O
adults O
) O
: O
May O
occur O
frequently O
. O

Reduce O
dose O
as O
necessary O
( O
5.7 O
) O
* O
Hypoadrenalism O
: O
Monitor O
patients O
for O
reduced O
serum O
cortisol O
levels O
and/or O
need O
for O
glucocorticoid O
dose O
increases O
in O
those O
with O
known O
hypoadrenalism O
( O
5.8 O
) O
* O
Hypothyroidism O
: O
May O
first O
become O
evident O
or O
worsen O
. O

Monitor O
thyroid O
function O
periodically O
( O
5.9 O
) O
* O
Slipped O
Capital O
Femoral O
Epiphysis O
: O
May O
develop O
. O

Evaluate O
children O
with O
the O
onset O
of O
a O
limp O
or O
hip/knee O
pain O
( O
5.10 O
) O
* O
Progression O
of O
Preexisting O
Scoliosis O
: O
Monitor O
any O
child O
with O
scoliosis O
for O
progression O
of O
the O
curve O
( O
5.11 O
) O
* O
Pancreatitis O
: O
Consider O
pancreatitis O
in O
patients O
with O
persistent O
severe O
abdominal O
pain O
( O
5.15 O
) O
5.1 O
Acute O
Critical O
Illness O
Increased O
mortality B-NonOSE_AE
in O
patients O
with O
acute B-Not_AE_Candidate
critical I-Not_AE_Candidate
illness I-Not_AE_Candidate
due O
to O
complications O
following O
open O
heart O
surgery O
, O
abdominal O
surgery O
or O
multiple O
accidental O
trauma O
, O
or O
those O
with O
acute B-Not_AE_Candidate
respiratory I-Not_AE_Candidate
failure I-Not_AE_Candidate
has O
been O
reported O
after O
treatment O
with O
pharmacologic O
amounts O
of O
somatropin O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Two O
placebo-controlled O
clinical O
trials O
in O
non B-Not_AE_Candidate
- I-Not_AE_Candidate
growth I-Not_AE_Candidate
hormone I-Not_AE_Candidate
deficient I-Not_AE_Candidate
adult O
patients O
( O
n=522 O
) O
with O
these O
conditions O
in O
intensive O
care O
units O
revealed O
a O
significant O
increase O
in O
mortality B-NonOSE_AE
( O
42 O
% O
vs O
. O
19 O
% O
) O
among O
somatropin-treated O
patients O
( O
doses O
5.3-8 O
mg/day O
) O
compared O
to O
those O
receiving O
placebo O
. O

The O
safety O
of O
continuing O
somatropin O
treatment O
in O
patients O
receiving O
replacement O
doses O
for O
approved O
indications O
who O
concurrently O
develop O
these O
illnesses O
has O
not O
been O
established O
. O

Therefore O
, O
the O
potential O
benefit O
of O
treatment O
continuation O
with O
somatropin O
in O
patients O
having O
acute B-Not_AE_Candidate
critical I-Not_AE_Candidate
illnesses I-Not_AE_Candidate
should O
be O
weighed O
against O
the O
potential O
risk O
. O

5.2 O
Prader-Willi O
Syndrome O
in O
Children O
There O
have O
been O
reports O
of O
fatalities B-NonOSE_AE
after O
initiating O
therapy O
with O
somatropin O
in O
pediatric O
patients O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
who O
had O
one O
or O
more O
of O
the O
following O
risk O
factors O
: O
severe B-Not_AE_Candidate
obesity I-Not_AE_Candidate
, O
history O
of O
upper B-Not_AE_Candidate
airway I-Not_AE_Candidate
obstruction I-Not_AE_Candidate
or O
sleep B-Not_AE_Candidate
apnea I-Not_AE_Candidate
, O
or O
unidentified O
respiratory B-Not_AE_Candidate
infection I-Not_AE_Candidate
. O

Male O
patients O
with O
one O
or O
more O
of O
these O
factors O
may O
be O
at O
greater O
risk O
than O
females O
. O

Patients O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
should O
be O
evaluated O
for O
signs O
of O
upper B-NonOSE_AE
airway I-NonOSE_AE
obstruction I-NonOSE_AE
and O
sleep B-NonOSE_AE
apnea I-NonOSE_AE
before O
initiation O
of O
treatment O
with O
somatropin O
. O

If O
during O
treatment O
with O
somatropin O
, O
patients O
show O
signs O
of O
upper B-NonOSE_AE
airway I-NonOSE_AE
obstruction I-NonOSE_AE
( O
including O
onset O
of O
or O
increased B-NonOSE_AE
snoring I-NonOSE_AE
) O
and/or O
new O
onset O
sleep B-NonOSE_AE
apnea I-NonOSE_AE
, O
treatment O
should O
be O
interrupted O
. O

All O
patients O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
treated O
with O
somatropin O
should O
also O
have O
effective O
weight O
control O
and O
be O
monitored O
for O
signs O
of O
respiratory B-NonOSE_AE
infection I-NonOSE_AE
, O
which O
should O
be O
diagnosed O
as O
early O
as O
possible O
and O
treated O
aggressively O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.3 O
Neoplasms O
In O
childhood O
cancer B-Not_AE_Candidate
survivors O
who O
were O
treated O
with O
radiation O
to O
the O
brain/head O
for O
their O
first O
neoplasm B-Not_AE_Candidate
and O
who O
developed O
subsequent O
GHD B-Not_AE_Candidate
and O
were O
treated O
with O
somatropin O
, O
an O
increased O
risk O
of O
a O
second B-OSE_Labeled_AE
neoplasm I-OSE_Labeled_AE
has O
been O
reported O
. O

Intracranial B-OSE_Labeled_AE
tumors I-OSE_Labeled_AE
, O
in O
particular O
meningiomas B-OSE_Labeled_AE
, O
were O
the O
most O
common O
of O
these O
second O
neoplasms B-NonOSE_AE
. O

In O
adults O
, O
it O
is O
unknown O
whether O
there O
is O
any O
relationship O
between O
somatropin O
replacement O
therapy O
and O
CNS B-NonOSE_AE
tumor I-NonOSE_AE
recurrence I-NonOSE_AE
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Monitor O
all O
patients O
with O
a O
history O
of O
GHD B-Not_AE_Candidate
secondary O
to O
an O
intracranial B-Not_AE_Candidate
neoplasm I-Not_AE_Candidate
routinely O
while O
on O
somatropin O
therapy O
for O
progression O
or O
recurrence B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
tumor I-NonOSE_AE
. O

Because O
children O
with O
certain O
rare O
genetic O
causes O
of O
short B-Not_AE_Candidate
stature I-Not_AE_Candidate
have O
an O
increased O
risk O
of O
developing O
malignancies B-NonOSE_AE
, O
practitioners O
should O
thoroughly O
consider O
the O
risks O
and O
benefits O
of O
starting O
somatropin O
in O
these O
patients O
. O

If O
treatment O
with O
somatropin O
is O
initiated O
, O
these O
patients O
should O
be O
carefully O
monitored O
for O
development O
of O
neoplasms B-NonOSE_AE
. O

Monitor O
patients O
on O
somatropin O
therapy O
carefully O
for O
increased B-NonOSE_AE
growth I-NonOSE_AE
, O
or O
potential O
malignant O
changes O
, O
of I-NonOSE_AE
preexisting I-NonOSE_AE
nevi I-NonOSE_AE
. O

5.4 O
Impaired B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
Tolerance I-OSE_Labeled_AE
and O
Diabetes O
Mellitus O
Treatment O
with O
somatropin O
may O
decrease B-OSE_Labeled_AE
insulin I-OSE_Labeled_AE
sensitivity I-OSE_Labeled_AE
, O
particularly O
at O
higher O
doses O
in O
susceptible O
patients O
. O

As O
a O
result O
, O
previously O
undiagnosed O
impaired B-Not_AE_Candidate
glucose I-Not_AE_Candidate
tolerance I-Not_AE_Candidate
and O
overt O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
may O
be O
unmasked O
during O
somatropin O
treatment O
. O

New B-OSE_Labeled_AE
- I-OSE_Labeled_AE
onset I-OSE_Labeled_AE
Type I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
diabetes I-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
has O
been O
reported O
. O

Therefore O
, O
glucose O
levels O
should O
be O
monitored O
periodically O
in O
all O
patients O
treated O
with O
somatropin O
, O
especially O
in O
those O
with O
risk O
factors O
for O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
, O
such O
as O
obesity B-Not_AE_Candidate
, O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
, O
or O
a O
family O
history O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
. O

Patients O
with O
preexisting O
type B-Not_AE_Candidate
1 I-Not_AE_Candidate
or O
type O
2 O
diabetes I-Not_AE_Candidate
mellitus I-Not_AE_Candidate
or O
impaired B-Not_AE_Candidate
glucose I-Not_AE_Candidate
tolerance I-Not_AE_Candidate
should O
be O
monitored O
closely O
during O
somatropin O
therapy O
. O

The O
doses O
of O
antihyperglycemic O
drugs O
( O
i.e. O
, O
insulin O
or O
oral/injectable O
agents O
) O
may O
require O
adjustment O
when O
somatropin O
therapy O
is O
instituted O
in O
these O
patients O
. O

5.5 O
Intracranial O
Hypertension O
Intracranial B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
( I-OSE_Labeled_AE
IH I-OSE_Labeled_AE
) O
with O
papilledema B-NonOSE_AE
, O
visual B-NonOSE_AE
changes I-NonOSE_AE
, O
headache B-NonOSE_AE
, O
nausea B-NonOSE_AE
and/or O
vomiting B-NonOSE_AE
has O
been O
reported O
in O
a O
small O
number O
of O
patients O
treated O
with O
somatropin O
products O
. O

Symptoms O
usually O
occurred O
within O
the O
first O
eight O
( O
8 O
) O
weeks O
after O
the O
initiation O
of O
somatropin O
therapy O
. O

In O
all O
reported O
cases O
, O
IH B-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
signs O
and O
symptoms O
rapidly O
resolved O
after O
cessation O
of O
therapy O
or O
a O
reduction O
of O
the O
somatropin O
dose O
. O

Funduscopic O
examination O
should O
be O
performed O
routinely O
before O
initiating O
treatment O
with O
somatropin O
to O
exclude O
preexisting O
papilledema O
, O
and O
periodically O
during O
the O
course O
of O
somatropin O
therapy O
. O

If O
papilledema B-NonOSE_AE
is O
observed O
by O
funduscopy O
during O
somatropin O
treatment O
, O
treatment O
should O
be O
stopped O
. O

If O
somatropin B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
IH I-NonOSE_AE
is O
diagnosed O
, O
treatment O
with O
somatropin O
can O
be O
restarted O
at O
a O
lower O
dose O
after O
IH B-NonOSE_AE
- I-NonOSE_AE
associated I-NonOSE_AE
signs O
and O
symptoms O
have O
resolved O
. O

Patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
and O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
may O
be O
at O
increased O
risk O
for O
the O
development O
of O
IH B-OSE_Labeled_AE
. O

5.6 O
Severe O
Hypersensitivity O
Serious O
systemic B-OSE_Labeled_AE
hypersensitivity I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
including O
anaphylactic B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
and O
angioedema B-OSE_Labeled_AE
have O
been O
reported O
with O
post-marketing O
use O
of O
somatropin O
products O
. O

Patients O
and O
caregivers O
should O
be O
informed O
that O
such O
reactions O
are O
possible O
and O
that O
prompt O
medical O
attention O
should O
be O
sought O
if O
an O
allergic O
reaction O
occurs O
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

5.7 O
Fluid O
Retention O
Fluid B-OSE_Labeled_AE
retention I-OSE_Labeled_AE
during O
somatropin O
replacement O
therapy O
in O
adults O
may O
occur O
. O

Clinical O
manifestations O
of O
fluid B-NonOSE_AE
retention I-NonOSE_AE
( O
e.g. O
, O
edema B-NonOSE_AE
, O
arthralgia B-NonOSE_AE
, O
myalgia B-NonOSE_AE
, O
nerve B-NonOSE_AE
compression I-NonOSE_AE
syndromes I-NonOSE_AE
including O
carpal B-NonOSE_AE
tunnel I-NonOSE_AE
syndrome I-NonOSE_AE
/ O
paraesthesias B-NonOSE_AE
) O
are O
usually O
transient O
and O
dose O
dependent O
. O

5.8 O
Hypoadrenalism O
Patients O
receiving O
somatropin O
therapy O
who O
have O
or O
are O
at O
risk O
for O
pituitary B-Not_AE_Candidate
hormone I-Not_AE_Candidate
deficiency I-Not_AE_Candidate
( O
s O
) O
may O
be O
at O
risk O
for O
reduced B-OSE_Labeled_AE
serum I-OSE_Labeled_AE
cortisol I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
and/or O
unmasking O
of O
central B-OSE_Labeled_AE
( I-OSE_Labeled_AE
secondary I-OSE_Labeled_AE
) I-OSE_Labeled_AE
hypoadrenalism I-OSE_Labeled_AE
. O

In O
addition O
, O
patients O
treated O
with O
glucocorticoid O
replacement O
for O
previously O
diagnosed O
hypoadrenalism B-Not_AE_Candidate
may O
require O
an O
increase O
in O
their O
maintenance O
or O
stress B-NonOSE_AE
doses I-NonOSE_AE
following O
initiation O
of O
somatropin O
treatment O
[ O
see O
Section O
7.1 O
, O
11-beta O
Hydroxysteroid O
Dehydrogenase O
Type O
1 O
] O
. O

5.9 O
Hypothyroidism O
Undiagnosed/untreated O
hypothyroidism B-Not_AE_Candidate
may O
prevent O
an O
optimal O
response O
to O
somatropin O
, O
in O
particular O
, O
the O
growth O
response O
in O
children O
. O

Patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
have O
an O
inherently O
increased O
risk O
of O
developing O
autoimmune B-NonOSE_AE
thyroid I-NonOSE_AE
disease O
and O
primary B-NonOSE_AE
hypothyroidism I-NonOSE_AE
. O

In O
patients O
with O
growth B-Not_AE_Candidate
hormone I-Not_AE_Candidate
deficiency I-Not_AE_Candidate
, O
central B-OSE_Labeled_AE
( I-OSE_Labeled_AE
secondary I-OSE_Labeled_AE
) I-OSE_Labeled_AE
hypothyroidism I-OSE_Labeled_AE
may O
first O
become O
evident O
or O
worsen O
during O
somatropin O
treatment O
. O

Therefore O
, O
patients O
treated O
with O
somatropin O
should O
have O
periodic O
thyroid O
function O
tests O
and O
thyroid O
hormone O
replacement O
therapy O
should O
be O
initiated O
or O
appropriately O
adjusted O
when O
indicated O
. O

5.10 O
Slipped O
Capital O
Femoral O
Epiphyses O
in O
Pediatric O
Patients O
Slipped B-OSE_Labeled_AE
capital I-OSE_Labeled_AE
femoral I-OSE_Labeled_AE
epiphyses I-OSE_Labeled_AE
may O
occur O
more O
frequently O
in O
patients O
with O
endocrine O
disorders O
( O
including O
GHD B-Not_AE_Candidate
and O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
) O
or O
in O
patients O
undergoing O
rapid B-NonOSE_AE
growth I-NonOSE_AE
. O

Any O
pediatric O
patient O
with O
the O
onset O
of O
a O
limp B-NonOSE_AE
or O
complaints O
of O
hip B-NonOSE_AE
or O
knee O
pain I-NonOSE_AE
during O
somatropin O
therapy O
should O
be O
carefully O
evaluated O
. O

5.11 O
Progression O
of O
Preexisting O
Scoliosis O
in O
Pediatric O
Patients O
Progression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
scoliosis I-OSE_Labeled_AE
can O
occur O
in O
patients O
who O
experience O
rapid B-NonOSE_AE
growth I-NonOSE_AE
. O

Because O
somatropin O
increases B-NonOSE_AE
growth I-NonOSE_AE
rate I-NonOSE_AE
, O
patients O
with O
a O
history O
of O
scoliosis B-Not_AE_Candidate
who O
are O
treated O
with O
somatropin O
should O
be O
monitored O
for O
progression O
of O
scoliosis B-NonOSE_AE
. O

However O
, O
somatropin O
has O
not O
been O
shown O
to O
increase O
the O
occurrence O
of O
scoliosis B-NonOSE_AE
. O

Skeletal B-NonOSE_AE
abnormalities I-NonOSE_AE
including O
scoliosis B-NonOSE_AE
are O
commonly O
seen O
in O
untreated O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
patients O
. O

Scoliosis B-NonOSE_AE
is O
also O
commonly O
seen O
in O
untreated O
patients O
with O
Prader B-Not_AE_Candidate
- I-Not_AE_Candidate
Willi I-Not_AE_Candidate
syndrome I-Not_AE_Candidate
. O

Physicians O
should O
be O
alert O
to O
these O
abnormalities O
, O
which O
may O
manifest O
during O
somatropin O
therapy O
. O

5.12 O
Otitis O
Media O
and O
Cardiovascular B-OSE_Labeled_AE
Disorders I-OSE_Labeled_AE
in O
Turner O
Syndrome O
Patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
should O
be O
evaluated O
carefully O
for O
otitis B-NonOSE_AE
media I-NonOSE_AE
and O
other O
ear B-NonOSE_AE
disorders I-NonOSE_AE
since O
these O
patients O
have O
an O
increased O
risk O
of O
ear B-NonOSE_AE
and O
hearing O
disorders I-NonOSE_AE
. O

Somatropin O
treatment O
may O
increase O
the O
occurrence O
of O
otitis B-OSE_Labeled_AE
media I-OSE_Labeled_AE
in O
patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
. O

In O
addition O
, O
patients O
with O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
should O
be O
monitored O
closely O
for O
cardiovascular B-NonOSE_AE
disorders I-NonOSE_AE
( O
e.g. O
, O
stroke B-NonOSE_AE
, O
aortic B-NonOSE_AE
aneurysm I-NonOSE_AE
/dissection O
, O
hypertension B-NonOSE_AE
) O
as O
these O
patients O
are O
also O
at O
risk O
for O
these O
conditions O
. O

5.13 O
Lipoatrophy O
When O
somatropin O
is O
administered O
subcutaneously O
at O
the O
same O
site O
over O
a O
long O
period O
of O
time O
, O
tissue B-NonOSE_AE
atrophy I-NonOSE_AE
may O
result O
. O

This O
can O
be O
avoided O
by O
rotating O
the O
injection O
site O
[ O
see O
Dosage O
and O
Administration O
. O

( O
2.3 O
) O
] O
. O

5.14 O
Laboratory O
Tests O
Serum O
levels O
of O
inorganic B-OSE_Labeled_AE
phosphorus I-OSE_Labeled_AE
, O
alkaline O
phosphatase O
, O
parathyroid O
hormone O
( O
PTH O
) O
and O
IGF-I O
may O
increase I-OSE_Labeled_AE
during O
somatropin O
therapy O
. O

5.15 O
Pancreatitis O
Cases O
of O
pancreatitis B-OSE_Labeled_AE
have O
been O
reported O
rarely O
in O
children O
and O
adults O
receiving O
somatropin O
treatment O
, O
with O
some O
evidence O
supporting O
a O
greater O
risk O
in O
children O
compared O
with O
adults O
. O

Published O
literature O
indicates O
that O
girls O
who O
have O
Turner B-Not_AE_Candidate
syndrome I-Not_AE_Candidate
may O
be O
at O
greater O
risk O
than O
other O
somatropin-treated O
children O
. O

Pancreatitis B-NonOSE_AE
should O
be O
considered O
in O
any O
somatropin-treated O
patient O
, O
especially O
a O
child O
, O
who O
develops O
persistent O
severe O
abdominal B-NonOSE_AE
pain I-NonOSE_AE
. O

